Response to Nivolumab is stratified by PD-L1 expression in AML-engrafted humanized mice.

(a) Overall survival curves of mice engrafted with either FA-AML-1 (cells with high PD-L1 expression) (PBS: n = 13, Nivolumab: n = 12) and (b) Kasumi-1 (cells with low PD-L1 expression) (PBS: n = 8, Nivolumab: n = 8). Spleen weights of mice that are PBS treated versus Nivolumab treated in (c) FA-AML-1 engrafted (PBS: n = 5, Nivolumab: n = 4) and (d) Kasumi-1 engrafted (PBS: n = 4, Nivolumab: n = 3) mice.